Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears SQI Multiplex Platform, Rheumatoid Arthritis Assay

NEW YORK (GenomeWeb News) – SQI Diagnostics today said that the US Food and Drug Administration has cleared for marketing its SQiDworks multiplex diagnostics platform and IgXPlex rheumatoid arthritis assay.

The SQiDworks automated platform uses the firm's IgXPlex technology to allow multiplexed measurement of target antibody sub-classes (IgA, IgG, IgM) for multiple biomarkers. The RA assay is used to aid in the diagnosis and monitoring of rheumatoid arthritis, RF-IgA, RF-IgM, and anti-CCP-IgG, a biomarker that has been rapidly adopted over the last five years, said Toronto-based SQI.

"We believe that combining our pipeline of multiplexed assays targeting autoimmune disease with our FDA-cleared system will be a tremendous competitive advantage in addressing our customers' needs," SQI CEO Claude Ricks said.

SQI's product pipeline for 2010 includes autoimmune test panels for irritable bowel disease, celiac disease, and lupus.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.